Reiman, Eric M.
Langbaum, Jessica B.
Tariot, Pierre N.
Lopera, Francisco
Bateman, Randall J.
Morris, John C.
Sperling, Reisa A.
Aisen, Paul S.
Roses, Allen D.
Welsh-Bohmer, Kathleen A.
Carrillo, Maria C.
Weninger, Stacie
Article History
First Online: 29 September 2015
Competing interests
: E.M.R. receives research support from Genentech, Eli Lilly/Avid Radiopharmaceuticals and Novartis. J.B.L. receives research support from Genentech and Novartis. P.N.T. has received research support from AC Immune, AstraZeneca, Avanir, Boehringer Ingelheim, Elan, Functional Neuromodulation, GE Healthcare, Genentech, Lilly, Lundbeck, Merck & Co., Novartis, Roche, Takeda and Targacept, and has personal financial interest in Abbott Laboratories, AbbVie, AC Immune, AstraZeneca, Auspex, Avanir, Boehringer Ingleheim, Chase Pharmaceuticals, Clintara, CME Group, Corium, GliaGure, Lilly, Lundbeck, Merck & Co., PlatformQ, Roche and Takeda. F.L. receives research support from Genentech. R.J.B. has received funding from Merck. He is a co-founder and part owner of C2N Diagnostics, and is a co-inventor on several patents under Washington University. He is on a scientific advisory board for FORUM pharmaceuticals, and has consulted for Eli Lilly, IMI, Merck, Novartis, Roche and Sanofi. J.C.M. is or was an investigator for clinical trials of antidementia drugs sponsored by the following companies: Janssen Immunotherapy, Pfizer, Eli Lilly/Avid Radiopharmaceuticals, the SNIFF study, and the A4 trial. He has consulted for Lilly USA, ISIS Pharmaceuticals and the Charles Dana Foundation. He receives research support from Eli Lilly/Avid Radiopharmaceuticals. R.A.S. has consulted for Biogen, Bracket, Genentech, Janssen and Roche. She receives research support from Eli Lilly and Co., Janssen Pharmaceuticals and Fidelity Biosciences. P.S.A. has consulted for the following companies: NeuroPhage, Eisai, Bristol-Myers Squibb, Eli Lilly, Merck, Roche, Amgen, Genentech, Novartis, Janssen, Biogen, iPerian, Anavex, Abbvie, Cohbar and Roivant. He has received research support from Eli Lilly and Janssen. A.D.R. is the CEO and only stock holder of Zinfandel Pharmaceuticals, which is allied with Takeda Pharmaceuticals. K.A.W.-B. receives research funding from Takeda through a contract with Duke University. S.W. is the Executive Director of the Fidelity Biosciences Research Initiative (FBRI), a subsidiary of Fidelity Investments. FBRI supports and facilitates the activities of the Collaboration for Alzheimer's Prevention and some of its affiliated studies. M.C.C. declares no competing interests.